Referencing Approved Drug Products in Abbreviated New Drug Application Submissions; Guidance for Industry; Availability

Resumen

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Referencing Approved Drug Products in Abbreviated New Drug Application Submissions." Any person is permitted to submit an abbreviated new drug application (ANDA) in order to seek approval to market a generic version of a previously approved drug product. The purpose of this guidance is to provide information to potential applicants on how to identify a reference listed drug (RLD), a reference standard, and the basis of submission in an ANDA submission.